TNFSF13 antibody

Catalog No. ABIN2664055

This anti-TNFSF13 antibody is a Mouse Monoclonal antibody detecting TNFSF13 in FACS. Suitable for Human.

Quick Overview for TNFSF13 antibody (ABIN2664055)

Target: TNFSF13 (Tumor Necrosis Factor (Ligand) Superfamily, Member 13 (TNFSF13))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This TNFSF13 antibody is un-conjugated

Application: Flow Cytometry (FACS)

Clone: 33H5

Product Details anti-TNFSF13 Antibody

Purification: The antibody was purified by affinity chromatography.

Isotype: IgG2a kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for TNFSF13

Target: TNFSF13 (Tumor Necrosis Factor (Ligand) Superfamily, Member 13 (TNFSF13))

Alternative Name: APRIL TNFSF13

Background: APRIL (A Proliferation-Inducing Ligand), also known as TNFSF13, stimulates cell proliferation. It is a member of the TNF superfamily of ligands, being most closely related to BAFF, with which it shares 30 % amino acid sequence identity. APRIL is cleaved intracellularly by furin and is believed to exist mainly in a secreted, soluble form. As with most other TNF family members, APRIL exists as a functional homotrimer (total MW = 90 kD). It can bind to two cell-surface receptors: BCMA and TACI, which it shares with BAFF, to exert downstream T- and B-cell regulatory effects. It also possesses a heparin binding domain and has been demonstrated to bind to proteoglycans on the cell surface. APRIL is most well known for its tumor proliferation effects. It is a potential biomarker, with serum levels elevated for certain cancers and expression levels elevated in cancer tissues. It is also a potential biomarker for certain autoimmune diseases. In fact, recombinant TACI has been brought to clinical trials as a neutralization drug against APRIL and BAFF for the treatment of systemic lupus erythematosus (SLE). Besides forming homotrimers, APRIL can also form functional heterotrimers with BAFF. The stoichiometric relationship of the protomeric units is still unclear, however, it appears that these heterotrimers are significant in that they are elevated in the serum of certain autoimmune patients. APRIL also forms an endogenous chimeric protein with another related protein, TWEAK, effectively called TWE-PRIL. It is believed that TWE-PRIL is membrane bound, and consists of the N-terminus of TWEAK with its transmembrane domain, and the C-terminus of APRIL with its receptor binding domain.

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response